Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
30 Cards in this Set
- Front
- Back
|
retroviruses:
reverse transcriptase intergrates viral -- into host ---- |
rna
dna |
|
|
viral oncongenes transform host cell to express ---, --- ----
|
oncongenes
growth factors malignant transformation |
|
|
host proto-oncogenes: host ---- genes that viral dna activates to transform cells
|
nonactive
|
|
|
unique features of hiv:
bind --- receptor on human ------- viral incoded reverse --- and ---- viral encoded ---- cleave functional --- ---- from precursors |
CD4
t lymphocytes transcriptase intergrase proteases viral protein |
|
|
goals of tx:
maximal and durable suppression of --- ------- |
viral load
HIV RNA < 50 copies/ml |
|
|
goals of tx
reudction of hiv --- and --- improvement of ---- resotoration of --- fx prevent --- ----- |
morbidity
mortality qol immunologic hiv transmission |
|
|
achieving goals of tx:
selection of initial --- tx maximize ---- to antiretroviral regimen rational ------- of drugs preservation of ---- tx options use of drug ------ testing in selected settings |
combo
adherance sequencing future resistance |
|
|
initiate tx for pts w/ --------defining illness or a CD4 t cells count < ----- cells/mm ^3
|
AIDS
350 |
|
|
initate tx for these people regardless of cd4 count
|
pregnant women
pt w/ hiv assocated nephropathy pts co-infected w/ hbv when hbv is indicated |
|
|
genotypic drug resistance for who?
|
all tx naive pts entering clincal care and if tx failure
|
|
|
why HLA-B 5701 testing prior to abacavi tx
|
because of hypersensitivity rxn
|
|
|
what test do you get prior to ccr5 antagonist
|
co-receptor tropsim testing
|
|
|
ccr5 changes to ---- or mixed ---- w/ decreased cd4 count
|
cxcr4
tropic |
|
|
when to check plasma viral rna
|
at baseline
regular basis chages in tx |
|
|
initial tx:
|
non-nucleoside reverse transcriptase inhibitor based
protease inibitor integrase stand transfer inhbitor based |
|
|
pregnant women tx
|
lopinavir and ritoavir
zidovudine/lamivudine |
|
|
preferred regimens
|
see slide
|
|
|
nucleotide analog inhbitors of reverse transcriptase
|
abacavir
didanosine emtricitabine lamivudine stavudine tenofovir df zidofudine |
|
|
nonnucleoside reverse transcriptase inhibitors
|
delavirdine
efavirenz etravirien nevirapine |
|
|
protease inhibitors
|
atazanair
darunavir fosamprenavir indinavir lopinavir/ritonavir nelfinavir ritonavir saquinavir tipranavir |
|
|
raltegravir inhibits integration of
|
viral dna into host dna
|
|
|
route of raltegravir
|
oral
|
|
|
t/f
decreased compliance of raltefravir due to se |
f
limited se |
|
|
receptors on cd cells
|
ccr5
cxcr4 mixture |
|
|
what is crucial for fusion of viral and host membranes
|
binding to cd4 receptors
|
|
|
what increases as cd4 decreases
|
cxcr4
|
|
|
ccr5 antagonist
|
maraviroc
|
|
|
route of marviroc:
|
oral
|
|
|
maraviroc metabolized by
|
cyp3a4
|
|
|
maravioc only effective against ---- ---
|
CCR5 HIV
|
